SCHEMBL8738405

SCHEMBL8738405

Cc1nc(Nc2ccccn2)sc1-c1csc(Nc2cc(C(N)=O)ccc2OC(C)C)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.58
MEN1 O00255 12/20 0.58
KMT2A Q03164 12/20 0.58
ALDH1A1 P00352 10/20 0.58
KDM4E B2RXH2 9/20 0.58
NPC1 O15118 5/20 0.58
RAB9A P51151 5/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
HTT P42858 5/20 0.58
LMNA P02545 4/20 0.58
GAA P10253 5/20 0.55
USP2 O75604 1/20 0.55
HSP90AA1 P07900 1/20 0.55
HSP90AB1 P08238 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TRPV4 Q9HBA0 1/20 0.53
CYP3A4 P08684 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 3/20 0.49
HPGD P15428 5/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8737954 0.90 MEN1 (0.48) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738335 0.89 MAPT (0.55) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738338 0.87 TRPV4 (0.52) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8737774 0.86 MMP9 (0.59) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738489 0.85 PIK3CG (0.60) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6114193 0.85 MEN1 (0.58) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738028 0.85 MEN1 (0.56) MAPTMEN1KMT2AALDH1A1KDM4E
Bromide SCHEMBL6114360 0.85 MMP9 (0.58) MAPTMEN1KMT2AALDH1A1KDM4E
Bromide SCHEMBL6113998 0.85 MEN1 (0.57) MAPTMEN1KMT2AALDH1A1KDM4E
Bromide SCHEMBL6113988 0.85 MEN1 (0.56) MAPTMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MAPT 3531/4885MEN1 2298/4885KMT2A 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.